ArticleBiochemistry and biophysics reports2025
LINC00592 is a predictor of poor lung adenocarcinoma outcomes that promotes tumor cell migration and invasion.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: The aim of this study was to examine the functional significance of the long noncoding RNA LINC00592 in lung adenocarcinoma (LUAD). Methods: Publicly available data were utilized to evaluate the expression of LINC00592 and its correlation with clinical characteristics. Additionally, the mechanistic and functional roles of this lncRNA were assessed in LUAD through colony formation assays, transwell assays, RNA-seq, and qPCR. Results: Upregulation and copy number amplification of LINC00592 were observed in LUAD and were found to be positively correlated with pathological stage, overall survival, progression-free survival, disease-specific survival, first-progression-free survival, and post-progression survival in LUAD patients. Silencing of LINC00592 impeded the ability of LUAD cells to migrate, invade, and form colonies, due to its ability to regulate the expression of NTN1, an important adhesion-related molecule. Conclusion: LINC00592 is a prognostic marker in LUAD patients and may represent a promising target for therapeutic intervention in this type of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.